4D Molecular Therapeutics clinical trials we track

Check company identity source

Phase 3 2 trials

Phase 2 2 trials

TrialDrugs studiedStatusPrimary completion
4D-710 in Adult Patients With Cystic FibrosisNCT052482304D-710Recruiting2027-06Estimated
4D-150 in Patients With Diabetic Macular EdemaNCT059305614D-150 IVT, Aflibercept IVTActive not recruiting2029-02-28Estimated

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Mean change from baseline in Best Corrected Visual Accuity (BCVA) Early Treatment for Diabetic Retinopathy (ETDRS) letter score at Week 52 Time frame: 52 Weeks. After: Measure: Mean change from baseline in Best Corrected Visual Acuity (BCVA) Early Treatment for Diabetic Retinopathy (ETDRS) letter score at Week 52 Time frame: 52 Weeks.

Primary completion date changed

Before: Nov 2028. After: Nov 2027.

Check registry source
4D-710 in Adult Patients With Cystic Fibrosis

NCT05248230 · 4D Molecular Therapeutics

· 2 fields changed

Planned enrollment decreased by 10 participants

Before: 40 participants (planned). After: 30 participants (planned).

Primary completion date changed

Before: Dec 2026. After: Jun 2027.

Check registry source